$363 Million is the total value of Foresite Capital Management III, LLC's 20 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 53.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AERI | Aerie Pharmaceuticals, Inc. | $94,793,000 | -7.5% | 1,950,477 | 0.0% | 26.11% | -22.0% | |
| ALDR | Buy | Alder BioPharmaceuticals, Inc. | $36,042,000 | +44.6% | 2,942,203 | +35.1% | 9.93% | +21.9% |
| IMMU | Buy | Immunomedics, Inc. | $33,264,000 | +94.1% | 2,379,367 | +22.6% | 9.16% | +63.7% |
| BPMC | Buy | Blueprint Medicines Corporation | $32,583,000 | +39.8% | 467,682 | +1.7% | 8.98% | +17.9% |
| AKAOQ | Buy | Achaogen, Inc. | $30,498,000 | +12.3% | 1,912,106 | +53.0% | 8.40% | -5.3% |
| AIMT | Aimmune Therapeutics, Inc. | $22,609,000 | +20.6% | 912,001 | 0.0% | 6.23% | +1.7% | |
| WVE | Sell | WAVE Life Sciences Ltd. | $18,777,000 | +0.5% | 863,327 | -14.0% | 5.17% | -15.2% |
| EPZM | Buy | Epizyme, Inc. | $16,187,000 | +34.1% | 849,693 | +6.3% | 4.46% | +13.1% |
| MYOK | New | Myokardia, Inc. | $12,641,000 | – | 295,000 | +100.0% | 3.48% | – |
| XLRN | Buy | Acceleron Pharma Inc. | $10,403,000 | +1622.4% | 278,753 | +1301.8% | 2.86% | +1354.3% |
| ASND | Buy | Ascendis Pharma A/Ssponsored adr | $10,336,000 | +1561.7% | 285,143 | +1173.0% | 2.85% | +1302.5% |
| VRNA | Sell | Verona Pharma Plcsponsored ads | $9,346,000 | +30.7% | 608,851 | -0.8% | 2.57% | +10.2% |
| ACRS | New | Aclaris Therapeutics, Inc. | $6,787,000 | – | 262,950 | +100.0% | 1.87% | – |
| PACB | Sell | Pacific Biosciences of California, Inc. | $6,038,000 | +35.7% | 1,150,000 | -8.0% | 1.66% | +14.4% |
| CBAY | New | CymaBay Therapeutics, Inc. | $4,836,000 | – | 600,000 | +100.0% | 1.33% | – |
| LOXO | Sell | Loxo Oncology, Inc. | $4,606,000 | -48.9% | 50,000 | -55.6% | 1.27% | -56.9% |
| MDGL | New | Madrigal Pharmaceuticals, Inc. | $4,498,000 | – | 100,000 | +100.0% | 1.24% | – |
| ARGX | argenx SEsponsored adr | $3,991,000 | +6.6% | 176,500 | 0.0% | 1.10% | -10.1% | |
| TOCA | Sell | Tocagen, Inc. | $3,653,000 | -59.7% | 293,177 | -61.1% | 1.01% | -66.0% |
| DERM | Sell | Dermira, Inc. | $1,163,000 | -77.4% | 43,071 | -75.6% | 0.32% | -80.9% |
| ABEO | Exit | Abeona Therapeutics, Inc. | $0 | – | -18,334 | -100.0% | -0.04% | – |
| ARDX | Exit | Ardelyx, Inc. | $0 | – | -37,500 | -100.0% | -0.06% | – |
| BHVN | Exit | Biohaven Pharmaceutical Holding Company Ltd. | $0 | – | -30,000 | -100.0% | -0.24% | – |
| ZFGN | Exit | Zafgen, Inc. | $0 | – | -234,092 | -100.0% | -0.27% | – |
| OREXQ | Exit | Orexigen Therapeutics, Inc. | $0 | – | -380,530 | -100.0% | -0.36% | – |
| INFI | Exit | Infinity Pharmaceuticals, Inc. | $0 | – | -738,896 | -100.0% | -0.38% | – |
| SGMO | Exit | Sangamo Therapeutics Inc. | $0 | – | -154,000 | -100.0% | -0.44% | – |
| NSTG | Exit | NanoString Technologies, Inc. | $0 | – | -178,681 | -100.0% | -0.96% | – |
| BLCM | Exit | Bellicum Pharmaceuticals, Inc. | $0 | – | -452,727 | -100.0% | -1.73% | – |
| FGEN | Exit | Fibrogen, Inc. | $0 | – | -250,000 | -100.0% | -2.64% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Epizyme, Inc. | 24 | Q3 2021 | 17.6% |
| Acceleron Pharma Inc. | 22 | Q3 2021 | 25.9% |
| CymaBay Therapeutics, Inc. | 20 | Q3 2022 | 17.6% |
| Aerie Pharmaceuticals, Inc. | 18 | Q1 2020 | 33.5% |
| Ascendis Pharma A/S | 17 | Q3 2022 | 47.8% |
| Alder BioPharmaceuticals, Inc. | 16 | Q3 2019 | 27.4% |
| Natera, Inc. | 16 | Q3 2022 | 21.5% |
| Aimmune Therapeutics, Inc. | 16 | Q3 2019 | 8.1% |
| Verona Pharma PLC. | 15 | Q3 2022 | 30.0% |
| WAVE Life Sciences Ltd. | 15 | Q2 2019 | 20.0% |
View Foresite Capital Management III, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
| 4 | 2021-11-03 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 3 | 2021-02-10 |
View Foresite Capital Management III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.